Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (101)

2024

  1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

2023

  1. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2

    Human Mutation, Vol. 2023

  2. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  3. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

    Genome Medicine, Vol. 15, Núm. 1

  4. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

    Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162

  5. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  6. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  7. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry

    International Journal of Cardiology, Vol. 370, pp. 51-57

  8. Impact of Post-PCI FFR Stratified by Coronary Artery

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 19, pp. 2396-2408

  9. Lung abscess and empyema in a heart transplant recipient from Thailand

    Transplant Infectious Disease, Vol. 25, Núm. 1

  10. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

  11. Practical Application of Coronary Physiologic Assessment: Asia-Pacific Expert Consensus Document: Part 1

    JACC: Asia, Vol. 3, Núm. 5, pp. 689-706

  12. Practical Application of Coronary Physiologic Assessment: Asia-Pacific Expert Consensus Document: Part 2

    JACC: Asia, Vol. 3, Núm. 6, pp. 825-842

  13. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    Kidney International, Vol. 103, Núm. 2, pp. 391-402

  14. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615

  15. Seven Additional Patients with SOX17 Related Pulmonary Arterial Hypertension and Review of the Literature

    Genes, Vol. 14, Núm. 10

  16. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  17. Survival after Invasive or Conservative Management of Stable Coronary Disease

    Circulation, Vol. 147, Núm. 1, pp. 8-19

  18. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE)

    World Allergy Organization Journal, Vol. 16, Núm. 3

  19. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222